Gan & Lee reports positive Phase 3 obesity trial results; J&J shares multiple myeloma data

Gan & Lee Pharmaceuticals, a China‑based insulin specialist, announced topline results from its Phase 3 obesity trial, indicating a successful outcome.

The company said the study met its primary endpoint, suggesting the investigational therapy could become a new option for patients with obesity.

At the same time, Johnson & Johnson presented new data on its multiple myeloma program, though specific details were not disclosed in the briefing.

The news brief also referenced updates from other companies, but the highlighted developments were the obesity readout and the myeloma data release.